About

Sun Pharmaceutical Industries (Sun Pharma) is one of India’s leading pharmaceutical companies that manufactures and sells pharmaceutical products primarily in the large markets of India and the United States. Lead by Rakesh Chandra Sinha since 2016, the multinational healthcare company’s legal team has performed exceptionally in recent years, particularly proving its worth in the context of a number of highly important M&A deals. Some of the major acquisitions the legal team worked on for Sun Pharma include the company’s acquisition of GSK’s Australian opiates business, as well as US-based eye care firm InSite Vision in 2015. The following year the legal team continued to provide examples of its outstanding support by working on the company’s purchase of US-based eye care specialist Ocular Technologies to further strengthen its branded ophthalmic portfolio. The team was also recognised for its outstanding work in the acquisition of an 85.1% stake in Russian pharmaceutical company Biosintez, in a deal that was worth $24m and will have the effect of enhancing Sun Pharma’s presence in the Russian market.